WO2005018424A3 - Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits - Google Patents

Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits Download PDF

Info

Publication number
WO2005018424A3
WO2005018424A3 PCT/US2004/026661 US2004026661W WO2005018424A3 WO 2005018424 A3 WO2005018424 A3 WO 2005018424A3 US 2004026661 W US2004026661 W US 2004026661W WO 2005018424 A3 WO2005018424 A3 WO 2005018424A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrillar amyloid
procedure
antibodies specific
detect
fibrillar
Prior art date
Application number
PCT/US2004/026661
Other languages
French (fr)
Other versions
WO2005018424A2 (en
Inventor
David L Miller
Pankaj Mehta
Jerzy Wegiel
Original Assignee
Res Found Mental Hygiene
David L Miller
Pankaj Mehta
Jerzy Wegiel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Mental Hygiene, David L Miller, Pankaj Mehta, Jerzy Wegiel filed Critical Res Found Mental Hygiene
Publication of WO2005018424A2 publication Critical patent/WO2005018424A2/en
Publication of WO2005018424A3 publication Critical patent/WO2005018424A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides novel antibodies, and antibody fragments, that specifically bind to fibrillar amyloid, and not to the non-fibrillar peptide. Also provided are methods for generating, identifying, and isolating the antibodies and antibody fragments of the invention. The antibodies described herein are useful in the study, diagnosis, and treatment of Alzheimer's disease.
PCT/US2004/026661 2003-08-18 2004-08-18 Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits WO2005018424A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49615203P 2003-08-18 2003-08-18
US60/496,152 2003-08-18

Publications (2)

Publication Number Publication Date
WO2005018424A2 WO2005018424A2 (en) 2005-03-03
WO2005018424A3 true WO2005018424A3 (en) 2006-04-27

Family

ID=34215965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/026661 WO2005018424A2 (en) 2003-08-18 2004-08-18 Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits

Country Status (1)

Country Link
WO (1) WO2005018424A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9580493B2 (en) 2011-06-23 2017-02-28 Biogen International Neuroscience Gmbh Anti-α synuclein binding molecules

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298807A3 (en) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
MX2009000476A (en) 2006-07-14 2009-01-28 Ac Immune Sa Humanized antibody against amyloid beta.
EA029481B1 (en) 2007-01-05 2018-04-30 Юнивэсэти Оф Цюрих Method for obtaining human recombinant antibody specifically binding a variant of endogenic protein that forms abnormal pathological protein structures by way of aggregation, oligomerisation, or fibril formation
AU2011265453B9 (en) * 2007-01-05 2013-09-12 University Of Zurich Method of providing disease-specific binding molecules and targets
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
AU2013204620B2 (en) * 2007-01-05 2015-09-17 University Of Zurich Method of Providing Disease-Specific Binding Molecules and Targets
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2730073A1 (en) * 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
EP2949666B1 (en) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
WO2010129276A2 (en) 2009-04-27 2010-11-11 Case Western Reserve University PYRO-GLUTAMATE Aβ TARGETING AGENTS
MX2012002993A (en) 2009-09-11 2012-04-19 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase.
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (en) 2010-03-10 2015-03-25 プロビオドルグ エージー Heterocyclic inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
ME02352B (en) * 2010-08-12 2016-06-20 Lilly Co Eli ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
DE102011057021A1 (en) 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Method for the selective quantification of A-beta aggregates
BR112014033066A2 (en) * 2012-07-03 2017-08-01 Janssen Alzheimer Immunotherap method for treating a patient diagnosed with alzheimer's disease, humanized, chimeric or antibody coated form, and, antibody.
DE102013106713A1 (en) * 2013-06-26 2014-12-31 Forschungszentrum Jülich GmbH Method for identifying indicators for the determination of diseases
MA41115A (en) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh ALZHEIMER'S DISEASE TREATMENT PROCESS
FI3672631T3 (en) 2017-08-22 2023-06-29 Biogen Ma Inc Pharmaceutical compositions containing anti-beta amyloid antibodies
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
US20220049009A1 (en) 2020-07-23 2022-02-17 Othair Prothena Limited Anti-Abeta Antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0613007A2 (en) * 1993-02-22 1994-08-31 Eli Lilly And Company Pharmaceutical screens and antibodies
US20030148392A1 (en) * 1992-07-10 2003-08-07 Athena Neurosciences, Inc. A Delaware Corporation Screening compounds for the ability to alter the production of amyloid-beta peptide (x-41)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148392A1 (en) * 1992-07-10 2003-08-07 Athena Neurosciences, Inc. A Delaware Corporation Screening compounds for the ability to alter the production of amyloid-beta peptide (x-41)
EP0613007A2 (en) * 1993-02-22 1994-08-31 Eli Lilly And Company Pharmaceutical screens and antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIGURDSSON E M ET AL: "Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice.", AM J PATHOL., vol. 159, no. 2, 1 August 2001 (2001-08-01), pages 439 - 447, XP008000840 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9580493B2 (en) 2011-06-23 2017-02-28 Biogen International Neuroscience Gmbh Anti-α synuclein binding molecules

Also Published As

Publication number Publication date
WO2005018424A2 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
MX2007013626A (en) Antibodies directed against amyloid-beta peptide and methods using same.
WO2000078344A8 (en) Prion protein peptides and uses thereof
TW200617023A (en) Antibodies directed against amyloid-beta peptide and methods using same
WO2005061545A3 (en) Nogoa antibodies for the treatment of alzheimer disease
WO2005012493A3 (en) Anti-cd19 antibodies
WO2003068821A3 (en) Anti-cd20 antibodies and fusion proteins thereof and methods of use
WO2002081505A3 (en) Peptide for the diagnosis and therapy of alzheimer's disease
RS80704A (en) ANTI- av?6.ANTIBODIES
AU2002237296A1 (en) Conformationally abnormal forms of tau proteins and specific antibodies thereto
TW200732348A (en) Monoclonal antibody
WO2003039467A3 (en) Monoclonal antibodies specific for beta-amyloid.
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
EP2277917A3 (en) B7-H3L cell surface target and a family of antibodies recognizing that target
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2004032975A3 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
HK1088909A1 (en) Peptide-based immunization therapy for treatment of atherosclerosis
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
WO2006108051A3 (en) Compositions and methods relating to alzheimer's disease
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2004007555A3 (en) Detection of prion disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase